Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Biden looks to boost supply chain for vaccines and other medicines
By
Kathleen Steele Gaivin
Nov 29, 2023
President Biden on Monday said he plans to use the Defense Production Act to make more “essential medicines” in America in an effort to mitigate drug shortages and curb inflation.
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
Paxlovid not helpful for reducing most post-COVID-19 conditions
Oct 31, 2023
No differences were seen in most post-COVID-19 conditions examined individually or by organ system, apart from a lower combined risk for venous thromboembolism and pulmonary embolism.
COVID-19 meds like Paxlovid will soon have big price tags
Oct 30, 2023
The pills still will be available at no cost until those bought earlier by the federal government run out.
Fluticasone furoate does not cut time to COVID-19 symptom resolution
Sep 21, 2023
No significant reduction was seen in the percent of patients with urgent care or emergency department visits or hospitalization.
Practice points developed for treatment of outpatient COVID-19
Sep 20, 2023
Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within five days of symptom onset.
Study looks at links between anxiety disorders, benzodiazepines, dementia
Aug 14, 2023
Benzodiazepines and anxiety disorders were linked to dementia risk, but no additional risk was seen for benzodiazepines in patients with anxiety disorders.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.